Investment Rating - The report assigns an "Outperform" rating for the company, indicating a positive outlook for its future performance [4]. Core Insights - The company is positioned as an innovative biopharmaceutical enterprise with a comprehensive industry chain layout and a clear direction for innovation, focusing on unmet clinical needs in oncology and aging-related diseases [2][9]. - The company has established a dual-driven innovation model through self-developed technologies and business development (BD) partnerships, enhancing its pipeline and market presence [2][4]. - The company is actively expanding its product offerings and entering new markets, with a focus on both domestic and international growth strategies [4][21]. Summary by Relevant Sections Company Overview - The company was founded in 2017 and went public on the Shanghai Stock Exchange in 2022, with plans for a Hong Kong listing to support its international expansion [9]. - The management team is experienced, with a stable shareholding structure, ensuring strategic decisions align with the company's core needs [11][13]. Research and Development - The company has multiple R&D platforms, including ADC, TCE, MyoDock™, and small nucleic acids, which work synergistically to achieve innovation and differentiation [22][23]. - The pipeline is rich, focusing on oncology for immediate returns while also developing anti-aging therapies for long-term growth [28]. Business Development Strategy - The company employs a diversified approach to business development, combining internal capabilities with external partnerships to maximize pipeline value [4][19]. - Collaborations with various partners, including local and global firms, are aimed at enhancing product commercialization and expanding market reach [4][21]. Financial Projections and Valuation - Revenue projections for 2025 to 2027 are estimated at 6.74 billion, 11.63 billion, and 12.73 billion RMB, respectively, indicating significant growth potential [4]. - The current market valuation is considered undervalued based on the company's projected cash flow and product pipeline [4]. Product Pipeline Highlights - The core product, Nectin-4 ADC (9MW2821), is in advanced clinical trials for multiple indications, including urothelial carcinoma and cervical cancer, with potential peak sales estimated at 1.988 billion RMB [31][33]. - The company is also developing innovative therapies for Alzheimer's disease and chronic obstructive pulmonary disease, showcasing its commitment to addressing critical health challenges [2][28].

Investment Rating - The report assigns an "Buy" rating for the company, marking the first coverage of its stock [4]. Core Insights - The company, Maiwei Biopharmaceuticals, is positioned as an innovative biopharmaceutical enterprise with a comprehensive industry chain layout and clear innovation direction, focusing on unmet clinical needs in oncology and aging-related diseases [2][9]. - The company has established a dual-driven innovation model through self-research and business development (BD), leveraging its unique technology platforms and differentiated product pipelines to create value [2][4]. - The revenue forecast for the company shows significant growth, with projected revenues of 674 million RMB in 2025, 1.163 billion RMB in 2026, and 1.273 billion RMB in 2027, reflecting a compound annual growth rate (CAGR) of 238% from 2024 to 2025 [4]. Summary by Sections Company Overview - Maiwei Biopharmaceuticals has transitioned from a "generic-innovative" model to a "global innovation" approach, with plans for a Hong Kong IPO to support its sustainable development and international expansion [9]. - The company has a stable shareholding structure and an experienced management team, with a focus on drug development and commercialization [11][13]. Research and Development - The company has multiple R&D platforms, including ADC, TCE, MyoDock™, and small nucleic acids, which work in synergy to achieve rapid innovation and differentiation [22][23]. - The pipeline is rich, with a focus on oncology products for immediate returns and anti-aging products for long-term growth [28]. Business Development Strategy - Maiwei has adopted a diversified and integrated approach to business development, forming partnerships to enhance product value and cash flow [4][19]. - The company is actively expanding its biosimilar drug business, which is crucial for cash flow, while also pursuing global market opportunities [4][19]. Financial Projections and Valuation - The company is expected to see a significant improvement in cash flow due to the anticipated success of its BD initiatives and the commercialization of its biosimilars [4]. - The estimated equity valuation of the company is 26.845 billion RMB, indicating that the current market valuation is undervalued [4].

【中泰研究丨晨会聚焦】固收吕品：节后还会延续修复吗？ 证券研究报告/晨会聚焦 2026 年 02 月 24 日 分析师：戴志锋 执业证书编号：S0740517030004 Email：daizf@zts.com.cn 欢迎关注中泰研究所订阅号 晨报内容回顾 1、《【中泰研究丨晨会聚焦】银行戴 志锋：银行 2025 年 4 季度经营数据： 净息差保持平稳，净利润增速转正》 2026-02-23 2、《【中泰研究丨晨会聚焦】宏观张 德礼：中国出口份额还有多大提升空 间？》2026-02-11 3、《【中泰研究丨晨会聚焦】固收吕 品：多空互加筹码，债市迎来"验牌 时刻"》2026-02-09 今日预览 【固收】吕品：节后还会延续修复吗？ 在过去一个多月，债市意外的走出了修复的行情，10 年下破 1.8%，TL 也站上 112.8 关键阻力位。 回顾年初以来的债市行情，基本多数品种都较 1 月初高点下行了 10BP 以上，5 年、7 年国债收益 率下行 14bp、13bp，7 年、10 年二永更是下行 20BP 以上。 我们在一月下旬就提示本轮修复行情，并在二月初《避险资产不避险，债市风景独好？》中提示 本轮 10 ...

Investment Rating - The report maintains a "Buy" rating for Wanhua Chemical [3] Core Insights - The polyurethane industry is experiencing a marginal improvement in supply and demand, indicating a cyclical recovery [4] - Wanhua Chemical is positioned as a leading player in the polyurethane market, benefiting from its scale and cost advantages [6][7] - The global MDI market is characterized by high barriers to entry, with Wanhua holding a significant market share [6][25] Summary by Relevant Sections Polyurethane Industry - The global polyurethane market is expected to grow from USD 91.49 billion in 2024 to USD 135.1 billion by 2032, with a CAGR of 4.4% [5][22] - MDI demand is projected to grow at a rate approximately double that of GDP, with global consumption expected to reach 8.54 million tons in 2024 [6][32] - The TDI market is also expected to see growth, with China's consumption projected to increase at an annual rate of 4.7% from 2023 to 2028 [6][8] Wanhua Chemical - Wanhua's core polyurethane raw material production capacity is set to increase from 4.16 million tons/year in 2021 to 6.86 million tons/year by the end of 2024 [6][7] - The company has a competitive edge due to its advanced MDI technology, which has undergone seven iterations, resulting in significant energy savings and lower production costs [7][8] - Wanhua's profitability is expected to recover, with projected net profits of CNY 12.31 billion, CNY 16.53 billion, and CNY 22.30 billion for 2025, 2026, and 2027 respectively [7][8] Profit Forecast and Valuation - The report forecasts a net profit growth rate of -6%, 34%, and 35% for the years 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 21.6x, 16.1x, and 11.9x [7][8]

化学制品 执业证书编号：S0740519070002 Email：sunying@zts.com.cn 执业证书编号：S0740524050001 1、《Q3 利润同比正增，持续看好周 期龙头》2025-10-26 2、《费用下降&产销量增，Q2 业绩 表现超预期》2025-08-12 长期发展》2025-07-26 万华化学（600309.SH） 证券研究报告/公司深度报告 2026 年 02 月 24 日 Email：zhangkun06@zts.com.cn 联系人：郝文阳 Email：haowy@zts.com.cn | 总股本(百万股) | 3,130.47 | | --- | --- | | 流通股本(百万股) | 3,130.47 | | 市价(元) | 84.96 | | 市值(百万元) | 265,964.87 | | 流通市值(百万元) | 265,964.87 | 股价与行业-市场走势对比 | 评级： | 买入（维持） | 公司盈利预测及估值 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 指标 | ...

Investment Rating - The industry investment rating is "Overweight" (maintained) [1] Core Insights - The report indicates that the social financing (社融) in January 2026 reached a new historical high for the same period, with an increase of 7.22 trillion yuan, which is 165.4 billion yuan more than the same period last year, exceeding the consensus expectation of 6.51 trillion yuan [4][7] - The report highlights that credit growth has slowed, with a notable decrease in loans to enterprises, while government bonds and corporate bonds have seen significant increases [4][12] - The liquidity and deposit situation shows a narrowing gap between M1 and M2 growth rates, with total deposits increasing by 8.09 trillion yuan, a year-on-year increase of 3.8 trillion yuan [18][20] Summary by Sections Social Financing Situation - In January 2026, social financing increased by 7.22 trillion yuan, up 165.4 billion yuan year-on-year, with a cumulative year-on-year growth rate of 8.2%, slightly down by 0.1 percentage points from December 2025 [4][7] - The main contributors to the increase were government bonds and bank acceptance bills, while credit growth was notably lower [8][9] Credit Situation - The total RMB loans increased by 4.71 trillion yuan in January, which is 420 billion yuan less than the same period last year, with a year-on-year growth rate of 6.1% [12][14] - The report details that household loans increased by 127 billion yuan year-on-year, while corporate loans decreased by 330 billion yuan [12][14] Liquidity and Deposit Situation - M1 and M2 growth rates both increased in January, with M1 growing by 4.9% and M2 by 9.0%, leading to a narrowing of the gap between the two [18][20] - Total deposits increased by 8.09 trillion yuan, with a year-on-year growth of 9.9%, while household deposits showed a significant decrease [20] Investment Recommendations - The report suggests a shift in the investment logic for bank stocks from "pro-cyclical" to "weak-cyclical," emphasizing the attractiveness of high dividend yields during periods of economic stagnation [23] - Two main investment lines are recommended: regional banks with strong certainty and large banks with high dividends [23]

Investment Rating - The industry investment rating is "Overweight" (maintained) [2] Core Insights - The report highlights that the "Five Major Articles" loans have surpassed 100 trillion yuan, accounting for nearly 40% of total loans, and continue to maintain a high growth rate, indicating a significant focus on this area for future credit [5][11] - New loan interest rates have seen a significant narrowing in year-on-year declines, with expectations of continued monetary easing, although comprehensive interest rate cuts will be approached with caution, suggesting that structural interest rate cuts may become the norm [5][18] Summary by Sections Section 1: "Five Major Articles" Credit Scale - The total balance of "Five Major Articles" loans reached 108.8 trillion yuan by the end of 2025, with a year-on-year growth of 12.9%, representing 39% of the total loan scale [11] - Traditional industries still dominate corporate loans, but their share is gradually declining, with real estate and infrastructure loans together accounting for over 50% of corporate loans as of Q4 2025 [11] - Technology loans are experiencing high growth, with small and medium-sized technology enterprises' loans at 3.6 trillion yuan, representing 1.9% of corporate loans, and high-tech enterprise loans growing at 19.1% year-on-year [11] - Green loans also show high growth, with a balance of 44.8 trillion yuan, a year-on-year increase of 20.2%, making up 24% of corporate loans [11] Section 2: New Loan Interest Rates - As of December 2025, the new loan interest rates for general loans, personal housing loans, and corporate loans were 3.55%, 3.06%, and 3.10%, respectively, with year-on-year declines of 27 basis points, 3 basis points, and 24 basis points [16] - The report indicates that the decline in new loan interest rates has narrowed significantly, with personal housing loan rates remaining stable for three consecutive quarters [16][18] Section 3: Investment Recommendations - The report suggests a shift in bank stocks from "pro-cyclical" to "weak-cyclical," emphasizing the stability and sustainability of the sector [20] - Two main investment lines are recommended: focusing on city and rural commercial banks with regional advantages and strong certainty, and large banks with high dividend yields [20]

Investment Rating - The industry investment rating is "Increase" [2][18] Core Insights - The penetration rate of cooking robots is increasing, driving the scale expansion of restaurant brands. The cooking robot market is expected to grow significantly, with a projected market size of 3.17 billion in 2024 and 11.7 billion by 2030 [7][12] - Labor costs in the restaurant industry are rising, with the proportion of labor costs reaching 28.6% in 2025, potentially exceeding 35% due to minimum wage increases and social security regulations. The shortage of chefs is projected to reach 3 million by 2025, making cooking robots essential for improving operational efficiency [8][12] - Major companies are investing in cooking robots to enhance operational efficiency, with deployment expected to exceed 150,000 restaurant locations by 2027. Cooking robots can reduce meal preparation time from 5-10 minutes to an average of 2-3 minutes, improving efficiency by over 40% and reducing labor costs by 40-60% [15][16] Summary by Sections Industry Overview - The industry comprises 128 listed companies with a total market value of 4,540.967 billion [4] Market Trends - The cooking robot market is rapidly expanding, with applications primarily in community canteens, group meals, and fast food scenarios. By 2028, the penetration rate in group meals and fast food is expected to reach around 50% [12][15] Company Developments - Companies like Guoquan, JD, and Zhengda are actively investing in the cooking robot sector, with significant deployments already in place. For instance, Guoquan plans to invest in cooking robot companies and has launched new projects [16]

Core Insights - The report emphasizes the importance of understanding market dynamics through three dimensions: policy, industry, and volatility, with the Chande theory focusing on the volatility aspect [3] - Chande theory consists of three components: fundamental analysis, comparative analysis, and technical analysis, with technical analysis being the closest to objective price facts and forming a high-probability trading system [3] Section Summaries Chande Theory Fundamentals - The Chande theory is built on three core principles: 1. Trends must complete and transform into new trends (upward/downward/consolidation) [4] 2. Self-similar structures indicate market fractal characteristics, with multiple levels of recursive definitions [4] 3. Three types of buy/sell points are defined: - First buy: trend bottom divergence (reversal point) - Second buy: secondary level pullback without breaking previous lows (confirmation point) - Third buy: breakout from the central area followed by a pullback without returning to the central area (acceleration point) [4][5] Technical Analysis Framework - The Chande framework includes a systematic breakdown with prerequisites and philosophical foundations, focusing on the following key points: - Segments must be broken by reverse segments, indicating the exhaustion of old energy and the establishment of new balance [5] - Any trend can be uniquely decomposed into three forms of connections at the same level [5] - Small divergences can trigger large-level reversals [5] Market Self-Similarity - The unique decomposition theorem states that any trend can be uniquely decomposed into a combination of trends and consolidations, resembling prime factorization [22] - The fractal nature of market movements allows for multi-level operations, where higher-level trends are defined by lower-level movements [23] Divergence and Buy/Sell Points - Divergence is a critical signal indicating the exhaustion of trend momentum, with two adjacent segments compared to identify strength changes [39] - The three types of buy/sell points provide a complete operational chain: - First type: trend divergence point, indicating potential reversals - Second type: confirmation point after a pullback - Third type: confirmation point after breaking out of a central area [39] Summary of Chande Theory - The Chande technical analysis system's three core principles create a tightly interconnected and logically sound system: - "Trends must complete" serves as the strategic guiding principle, establishing the ultimate laws of market operation - "Self-similar structures and levels" provide standardized tools for market dissection - "Divergence and buy/sell points" offer precise entry and exit signals for trading decisions [52]

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [3]. Core Insights - The company is a leading player in the automotive exterior and structural components sector, expanding into new areas such as robotics and liquid cooling. The battery box segment has shown the fastest growth, with revenue share increasing from 1.8% in 2021 to 21.8% in 2024 [5][10]. - The company has a strong focus on R&D, maintaining a research and development expense ratio above 6% since 2020, significantly ahead of peers [5][24]. - The company has established a global localized operation strategy, with 77 factories and offices across 14 countries, serving over 80 automotive brands [5][31]. Financial Performance - Revenue is projected to grow from 20,524 million in 2023 to 35,752 million in 2027, with a CAGR of approximately 16.7% from 2020 to 2024 [3][10]. - Net profit is expected to rise from 1,903 million in 2023 to 3,729 million in 2027, reflecting a growth rate of 15% to 18% year-on-year [3][10]. - The company’s capital expenditure is expected to decrease significantly in 2024, dropping to 19.38 billion, a 41% reduction from the previous year [15]. Product Structure and Market Position - The company's main products include plastic parts, metal trims, copper and aluminum forgings, and battery boxes, with battery boxes being the fastest-growing segment [5][10]. - The company has seen a significant increase in overseas revenue, with a CAGR of 28.5% from 2020 to 2024, and overseas revenue accounting for nearly 65% of total revenue in 2025 [12][13]. Growth Opportunities - The global battery box market is projected to reach 1,081.8 billion by 2027, with a CAGR of approximately 25% from 2023 to 2027 [5][42]. - The company is diversifying into robotics and liquid cooling, leveraging its existing capabilities in aluminum processing and plastic manufacturing [5][59]. Customer Base and Expansion - The customer base has evolved from primarily Japanese clients to a more diversified portfolio including European and American brands, with European clients expected to account for 26.6% of revenue by 2024 [5][13][33]. - The company has secured over 130 billion in orders for battery boxes, indicating strong future revenue potential [5][55].